Pharmacokinetics of tuberculosis drugs in HIV-infected patients from Irkutsk, Russian Federation: redefining drug activity

Galina Lyles¹, Oleg Ogarkov^{2

3

4}, Svetlana Zhdanova², Charles A Peloquin⁵, Andrew Ebers⁶, Herman Pfaeffle⁷, Mohammad H Al-Shaer⁵, Elena Moiseeva⁴, Elena Zorkaltseva^{3

4}, Mikhail Koscheev⁴, Eric R Houpt⁶, Scott K Heysell⁶

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, VA, USA.
² Scientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russia.
³ Irkutsk State Medical Academy of Continuing Education, Irkutsk, Russia.
⁴ Irkutsk Clinical Tuberculosis Hospital, Irkutsk, Russia.
⁵ College of Pharmacy, University of Florida, Gainesville, FL, USA.
⁶ Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
⁷ School of Medicine, University of Virginia, Charlottesville, VA, USA.

Galina Lyles et al. Eur Respir J. 2018.

. 2018 May 24;51(5):1800109.

doi: 10.1183/13993003.00109-2018. Print 2018 May.

¹ Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, VA, USA.
² Scientific Centre for Family Health and Human Reproduction Problems, Irkutsk, Russia.
³ Irkutsk State Medical Academy of Continuing Education, Irkutsk, Russia.
⁴ Irkutsk Clinical Tuberculosis Hospital, Irkutsk, Russia.
⁵ College of Pharmacy, University of Florida, Gainesville, FL, USA.
⁶ Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
⁷ School of Medicine, University of Virginia, Charlottesville, VA, USA.

No abstract available

Conflict of interest statement

Conflict of interest: None declared.

Urine colorimetry for levofloxacin pharmacokinetics and personalized dosing in people with drug-resistant tuberculosis.
Rao P, Zhdanova S, Ogarkov O, Orlova E, Ebers A, Stroup S, Mirawdaly S, Aartsen DV, Koshkina O, Suzdalnitsky A, Moiseeva E, Dillingham R, Heysell SK. Rao P, et al. Int J Mycobacteriol. 2020 Oct-Dec;9(4):411-416. doi: 10.4103/ijmy.ijmy_186_20. Int J Mycobacteriol. 2020. PMID: 33323657 Free PMC article.

1. World Health Organization. Global Tuberculosis Report 2017 WHO/HTM/TB/2017.23 Geneva, World Health Organization, 2017. Available from: www.who.int/tb/publications/global_report/en/
1. Heysell SK, Ogarkov OB, Zhdanova S, et al. Undertreated HIV and drug-resistant tuberculosis at a referral hospital in Irkutsk, Siberia. Int J Tuberc Lung Dis 2016; 20: 187–192. - PMC - PubMed
1. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010; 181: 80–86. - PubMed
1. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003; 167: 1341–1347. - PubMed
1. Vinnard C, Ravimohan S, Tamuhla N, et al. Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation. Br J Clin Pharmacol 2017; 83: 801–811. - PMC - PubMed